ValuEngine upgraded shares of Eagle Pharmaceuticals (NASDAQ:EGRX) from a sell rating to a hold rating in a research note published on Friday, May 11th.
EGRX has been the topic of several other research reports. Zacks Investment Research downgraded Eagle Pharmaceuticals from a hold rating to a strong sell rating in a research note on Thursday, March 1st. Piper Jaffray Companies reaffirmed a buy rating and set a $79.00 target price on shares of Eagle Pharmaceuticals in a research note on Tuesday, January 30th. Mizuho reaffirmed an underperform rating and set a $40.00 target price (up previously from $37.00) on shares of Eagle Pharmaceuticals in a research note on Wednesday, March 21st. BidaskClub downgraded Eagle Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, January 18th. Finally, Royal Bank of Canada set a $71.00 target price on Eagle Pharmaceuticals and gave the company a buy rating in a research note on Monday, February 26th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Eagle Pharmaceuticals has an average rating of Hold and a consensus price target of $68.00.
Eagle Pharmaceuticals opened at $65.36 on Friday, Marketbeat Ratings reports. Eagle Pharmaceuticals has a 12-month low of $45.05 and a 12-month high of $84.20. The company has a market cap of $969.64 million, a P/E ratio of 19.39 and a beta of 1.39. The company has a quick ratio of 5.66, a current ratio of 5.87 and a debt-to-equity ratio of 0.23.
Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings data on Thursday, May 10th. The specialty pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.68 by ($0.15). The company had revenue of $46.60 million for the quarter, compared to analyst estimates of $48.88 million. Eagle Pharmaceuticals had a net margin of 15.32% and a return on equity of 21.89%. The company’s revenue for the quarter was down 39.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.42 EPS. equities analysts expect that Eagle Pharmaceuticals will post 1.92 EPS for the current fiscal year.
In other news, Director Sander A. Flaum sold 2,340 shares of the business’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $53.94, for a total value of $126,219.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 19.50% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of EGRX. Wells Fargo & Company MN raised its stake in shares of Eagle Pharmaceuticals by 35.5% in the 3rd quarter. Wells Fargo & Company MN now owns 21,506 shares of the specialty pharmaceutical company’s stock worth $1,283,000 after buying an additional 5,640 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Eagle Pharmaceuticals by 63.9% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 60,716 shares of the specialty pharmaceutical company’s stock worth $3,622,000 after buying an additional 23,663 shares in the last quarter. Bowling Portfolio Management LLC bought a new stake in shares of Eagle Pharmaceuticals in the 4th quarter worth $1,806,000. Fisher Asset Management LLC raised its stake in shares of Eagle Pharmaceuticals by 24.5% in the 4th quarter. Fisher Asset Management LLC now owns 29,784 shares of the specialty pharmaceutical company’s stock worth $1,591,000 after buying an additional 5,863 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of Eagle Pharmaceuticals by 63.7% in the 4th quarter. SG Americas Securities LLC now owns 7,385 shares of the specialty pharmaceutical company’s stock worth $395,000 after buying an additional 2,874 shares in the last quarter.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.